id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-N-2590-0003,FDA,FDA-2026-N-2590,List of References_FDA-2026-N-2590,Supporting & Related Material,Background Material,2026-04-20T04:00:00Z,2026,4,,,2026-04-20T20:30:47Z,,0,0,09000064b9281c66
FDA-2026-N-2590-0007,FDA,FDA-2026-N-2590,Reference 4 - P180047 Summary of Safety and Effectiveness Data,Supporting & Related Material,Background Material,2026-04-20T04:00:00Z,2026,4,,,2026-04-20T20:31:22Z,,0,0,09000064b9288104
FDA-2026-N-2590-0008,FDA,FDA-2026-N-2590,Reference 5 - P070006 Summary of Safety and Effectiveness Data,Supporting & Related Material,Background Material,2026-04-20T04:00:00Z,2026,4,,,2026-04-20T20:31:25Z,,0,0,09000064b9288105
FDA-2026-N-2590-0010,FDA,FDA-2026-N-2590,Reference 7 - 2023_ Microbiology Devices Panel of the Medical Devices Advisory Committee Meeting Announcement,Supporting & Related Material,Background Material,2026-04-20T04:00:00Z,2026,4,,,2026-04-20T20:31:31Z,,0,0,09000064b9288107
FDA-2026-N-2590-0011,FDA,FDA-2026-N-2590,Reference 8 - Diagnosis of Tuberculosis in Adults and Children,Supporting & Related Material,Background Material,2026-04-20T04:00:00Z,2026,4,,,2026-04-20T20:31:35Z,,0,0,09000064b9288108
FDA-2026-N-2590-0005,FDA,FDA-2026-N-2590,Reference 2 - 2001 Microbiology Devices Panel Meeting Summary,Supporting & Related Material,Background Material,2026-04-20T04:00:00Z,2026,4,,,2026-04-20T20:31:03Z,,0,0,09000064b9288102
FDA-2026-N-2590-0012,FDA,FDA-2026-N-2590,Reference 9 - Treatment of Drug-Susceptible Tuberculosis,Supporting & Related Material,Background Material,2026-04-20T04:00:00Z,2026,4,,,2026-04-20T20:31:37Z,,0,0,09000064b9288109
FDA-2026-N-2590-0006,FDA,FDA-2026-N-2590,Reference 3 - P010033 Summary of Safety and Effectiveness Data,Supporting & Related Material,Background Material,2026-04-20T04:00:00Z,2026,4,,,2026-04-20T20:31:19Z,,0,0,09000064b9288103
FDA-2026-N-2590-0009,FDA,FDA-2026-N-2590,Reference 6 - 2011 Meeting Materials of the Microbiology Devices Panel,Supporting & Related Material,Background Material,2026-04-20T04:00:00Z,2026,4,,,2026-04-20T20:31:28Z,,0,0,09000064b9288106
FDA-2026-N-2590-0004,FDA,FDA-2026-N-2590,Reference 1 - P010033 Approval Order,Supporting & Related Material,Background Material,2026-04-20T04:00:00Z,2026,4,,,2026-04-20T20:31:00Z,,0,0,09000064b9288101
FDA-2026-N-2590-0001,FDA,FDA-2026-N-2590,Microbiology Devices; Reclassification of Mycobacterium Tuberculosis Cell-Mediated Immunity Tests and Immune Response Enzyme-Linked Immunospot Tests,Proposed Rule,Request for Comment,2026-03-30T04:00:00Z,2026,3,2026-03-30T04:00:00Z,2026-05-30T03:59:59Z,2026-05-13T09:00:24Z,2026-06064,1,0,09000064b92437b6